

# DIN EN ISO 11137-2:2023-08 (E)

## Sterilization of health care products - Radiation - Part 2: Establishing the sterilization dose (ISO 11137-2:2013 + Amd 1:2022) (includes Amendment A1:2023)

---

| <b>Contents</b> |   | <b>Page</b> |
|-----------------|---|-------------|
|                 | European foreword .....   | 4           |
|                 | European foreword to Amendment .....  | 5           |
|                 | Foreword to Amendment .....   | 6           |
|                 | Introduction .....  | 7           |
| <b>1</b>        | <b>Scope .....</b>  | <b>8</b>    |
| <b>2</b>        | <b>Normative references .....</b>   | <b>8</b>    |
| <b>3</b>        | <b>Terms, definitions, and abbreviated terms .....</b>  | <b>8</b>    |
| <b>3.1</b>      | <b>Terms and definitions .....</b>  | <b>8</b>    |
| <b>3.2</b>      | <b>Abbreviated terms .....</b>  | <b>10</b>   |
| <b>4</b>        | <b>Definition and maintenance of product families for dose setting, dose substantiation, and sterilization dose auditing .....</b>              | <b>11</b>   |
| <b>4.1</b>      | <b>General .....</b>  | <b>11</b>   |
| <b>4.2</b>      | <b>Defining product families .....</b>  | <b>11</b>   |
| <b>4.3</b>      | <b>Designation of product to represent a product family for performance of a verification dose experiment or sterilization dose audit .....</b> | <b>12</b>   |
| <b>4.4</b>      | <b>Maintaining product families .....</b>   | <b>13</b>   |
| <b>4.5</b>      | <b>Effect of failure of establishment of sterilization dose or of a sterilization dose audit on a product family .....</b>                      | <b>14</b>   |
| <b>5</b>        | <b>Selection and testing of product for establishing the sterilization dose .....</b>   | <b>14</b>   |
| <b>5.1</b>      | <b>Nature of product .....</b>  | <b>14</b>   |
| <b>5.2</b>      | <b>Sample item portion (SIP) .....</b>  | <b>15</b>   |
| <b>5.3</b>      | <b>Manner of sampling .....</b>   | <b>16</b>   |
| <b>5.4</b>      | <b>Microbiological testing .....</b>  | <b>16</b>   |
| <b>5.5</b>      | <b>Irradiation .....</b>  | <b>16</b>   |
| <b>6</b>        | <b>Methods of dose establishment .....</b>  | <b>16</b>   |
| <b>7</b>        | <b>Method 1: dose setting using bioburden information .....</b>   | <b>17</b>   |
| <b>7.1</b>      | <b>Rationale .....</b>  | <b>17</b>   |
| <b>7.2</b>      | <b>Procedure for Method 1 for product with an average bioburden greater than or equal to 1,0 for multiple production batches .....</b>          | <b>18</b>   |
| <b>7.3</b>      | <b>Procedure for Method 1 for product with an average bioburden greater than or equal to 1,0 for a single production batch .....</b>            | <b>24</b>   |
| <b>7.4</b>      | <b>Procedure for Method 1 for product with an average bioburden in the range 0,1 to 0,9 for multiple or single production batches .....</b>     | <b>26</b>   |
| <b>8</b>        | <b>Method 2: Dose setting using fraction positive information from incremental dosing to determine an extrapolation factor .....</b>            | <b>27</b>   |
| <b>8.1</b>      | <b>Rationale .....</b>  | <b>27</b>   |
| <b>8.2</b>      | <b>Procedure for Method 2A .....</b>  | <b>28</b>   |
| <b>8.3</b>      | <b>Procedure for Method 2B .....</b>  | <b>31</b>   |
| <b>9</b>        | <b>Method VD<sub>max</sub> -- Substantiation of a selected sterilization dose .....</b>   | <b>35</b>   |
| <b>9.1</b>      | <b>Selected doses and rationale .....</b>   | <b>35</b>   |
| <b>9.2</b>      | <b>Procedure for Method VD<sub>max25</sub> for multiple production batches .....</b>  | <b>36</b>   |
| <b>9.3</b>      | <b>Procedure for Method VD<sub>max25</sub> for a single production batch .....</b>  | <b>41</b>   |
| <b>9.4</b>      | <b>Procedure for Method VD<sub>max15</sub> for multiple production batches .....</b>  | <b>44</b>   |
| <b>9.5</b>      | <b>Procedure for Method VD<sub>max15</sub> for a single production batch .....</b>  | <b>47</b>   |

|   |   |           |
|---|---|-----------|
| <b>10</b>   | <b>Sterilization dose audit .....</b>   | <b>50</b> |
| <b>10.1</b>   | <b>Purpose and frequency .....</b>  | <b>50</b> |
| <b>10.2</b>   | <b>Procedure for auditing a sterilization dose established using Method 1, Method 2A, or Method 2B .....</b>  | <b>50</b> |
| <b>10.3</b>   | <b>Procedure for auditing a sterilization dose substantiated using Method VDmax25 or Method VDmax15 .....</b>   | <b>53</b> |
| <b>10.4</b>   | <b>Failure of a sterilization dose audit .....</b>  | <b>59</b> |
| <b>11</b>   | <b>Worked examples .....</b>  | <b>59</b> |
| <b>11.1</b>   | <b>Worked examples for Method 1 .....</b>   | <b>59</b> |
| <b>11.2</b>   | <b>Worked examples for Method 2 .....</b>   | <b>61</b> |
| <b>11.3</b>   | <b>Worked examples for Method VDmax .....</b>   | <b>69</b> |
| <b>11.4</b>   | <b>Worked example of a sterilization dose audit for a dose established using Method 1, the findings from which necessitated augmentation of the sterilization dose .....</b>  | <b>71</b> |
| <b>11.5</b>   | <b>Worked example of a sterilization dose audit for a dose established using Method 2A, the findings from which necessitated augmentation of the sterilization dose .....</b> | <b>71</b> |
| <b>11.6</b>   | <b>Worked example of a sterilization dose audit for a sterilization dose substantiated using Method VDmax25 .....</b>   | <b>72</b> |
| <b>Annex ZA (informative) Relationship between this European Standard and the General Safety and Performance Requirements of Regulation (EU) 2017/745 aimed to be covered .....</b> |   | <b>74</b> |
| <b>Annex ZB (informative) Relationship between this European Standard and the General Safety and Performance Requirements of Regulation (EU) 2017/746 aimed to be covered .....</b> |   | <b>77</b> |
| <b>Bibliography .....</b>   |   | <b>79</b> |